[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 31st that it has signed a supply contract for plasmid DNA pharmaceuticals worth 5.8 million dollars, which will be the first production from its new factory. The contracting party has not been disclosed according to the contract, and the total contract amount is approximately 7.2 billion KRW when converted to Korean won.
Jinwon Life Sciences' subsidiary VGXI produces and supplies high-quality plasmid DNA pharmaceuticals as a contract development and manufacturing organization (CDMO) facility compliant with current Good Manufacturing Practice (cGMP) standards. In October last year, it completed a new first factory at Deison Technology Park in Conroe, Texas, USA, capable of differentiated large-scale, high-quality plasmid DNA CDMO production.
Park Young-geun, CEO of Jinwon Life Sciences, said, "We are pleased to have signed the first supply contract for products produced at the new factory," and added, "We will continue steady sales activities to secure the increasing demand for high-quality plasmid DNA pharmaceuticals and focus on improving performance."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
